Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants

References

• Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics 2009;123:1562–73
   PubMed Web of Science ®Google Scholar
• Ambalavanan N, Carlo WA, D’Angio CT, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 2009;123:1132–41
   PubMed Web of Science ®Google Scholar
• Viscardi RM, Muhumuza CK, Rodriguez A, et al. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res 2004;55:1009–17
   PubMed Web of Science ®Google Scholar
• Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003;14:523–35
   PubMed Web of Science ®Google Scholar
• Aghai ZH, Faqiri S, Saslow JG, et al. Angiopoietin 2 concentrations in infants developing bronchopulmonary dysplasia: attenuation by dexamethasone. J Perinatol 2008;28:149–55
   PubMed Web of Science ®Google Scholar
• Aghai ZH, Saslow JG, Meniru C, et al. High-mobility group box-1 protein in tracheal aspirates from premature infants: relationship with bronchopulmonary dysplasia and steroid therapy. J Perinatol 2010;30:610–15
   PubMed Web of Science ®Google Scholar
• Jonsson B, Tullus K, Brauner A, et al. Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1997;77:F198–201
   Web of Science ®Google Scholar
• Choi CW, Kim BI, Kim HS, et al. Increase of interleukin-6 in tracheal aspirate at birth: a predictor of subsequent bronchopulmonary dysplasia in preterm infants. Acta Paediatr 2006;95:38–43
   PubMed Web of Science ®Google Scholar
• Munshi UK, Niu JO, Siddiq MM, Parton LA. Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol 1997;24:331–6
   PubMed Web of Science ®Google Scholar
• Chavez-Valdez R, Wills-Karp M, Ahlawat R, et al. Caffeine modulates TNF-alpha production by cord blood monocytes: the role of adenosine receptors. Pediatr Res 2009;65:203–8
   PubMed Web of Science ®Google Scholar
• Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J 2013;41:966–73
   PubMed Web of Science ®Google Scholar
• Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112–21
   PubMed Web of Science ®Google Scholar
• Davis PG, Schmidt B, Roberts RS, et al. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. J Pediatr 2010;156:382–7
   PubMed Web of Science ®Google Scholar
• Patel RM, Leong T, Carlton DP, Vyas-Read S. Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol 2013;33:134–40
   PubMed Web of Science ®Google Scholar
• Erenberg A, Leff RD, Haack DG, et al. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy 2000;20:644–52
   PubMed Web of Science ®Google Scholar
• Kim BI, Lee HE, Choi CW, et al. Increase in cord blood soluble E-selectin and tracheal aspirate neutrophils at birth and the development of new bronchopulmonary dysplasia. J Perinat Med 2004;32:282–7
   PubMed Web of Science ®Google Scholar
• Li J, Li G, Hu JL, et al. Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A2A receptor-independent mechanism. Eur J Pharmacol 2011;654:295–303
   PubMed Web of Science ®Google Scholar
• Bohrer B, Silveira RC, Neto EC, Procianoy RS. Mechanical ventilation of newborns infant changes in plasma pro- and anti-inflammatory cytokines. J Pediatr 2010;156:16–19
   PubMed Web of Science ®Google Scholar
• Aranda JV, Turmen T, Davis J, et al. Effect of caffeine on control of breathing in infantile apnea. J Pediatr 1983;103:975–8
   PubMed Web of Science ®Google Scholar
• Davis JM, Bhutani VK, Stefano JL, et al. Changes in pulmonary mechanics following caffeine administration in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1989;6:49–52
   PubMed Web of Science ®Google Scholar
• Supinski GS, Deal Jr EC, Kelsen SG. The effects of caffeine and theophylline on diaphragm contractility. Am Rev Respir Dis 1984;130:429–33
   PubMed Web of Science ®Google Scholar
• Yoder B, Thomson M, Coalson J. Lung function in immature baboons with respiratory distress syndrome receiving early caffeine therapy: a pilot study. Acta Paediatr 2005;94:92–8
   PubMed Web of Science ®Google Scholar
• Schmidt B, Roberts R, Millar D, Kirpalani H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 2008;93:284–7
   PubMed Web of Science ®Google Scholar
• Thomas W, Speer CP. Nonventilatory strategies for prevention and treatment of bronchopulmonary dysplasia – what is the evidence? Neonatology 2008;94:150–9
   PubMed Web of Science ®Google Scholar
• Volpe J, ed. Neurology of the newborn. Philadelphia (PA): WB Saunders; 2001
   Google Scholar
• Bauer J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics 2001;107:660–3
   PubMed Web of Science ®Google Scholar
• Hoecker C, Nelle M, Poeschl J, et al. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics 2002;109:784–7
   PubMed Web of Science ®Google Scholar
• Lane AJ, Coombs RC, Evans DH, Levin RJ. Effect of caffeine on neonatal splanchnic blood flow. Arch Dis Child Fetal Neonatal Ed 1999;80:F128–9
   PubMed Web of Science ®Google Scholar
• Soraisham AS, Elliott D, Amin H. Effect of single loading dose of intravenous caffeine infusion on superior mesenteric artery blood flow velocities in preterm infants. J Paediatr Child Health 2008;44:119–21
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Clayden GS, Smith MF. Xanthines and necrotising enterocolitis. Arch Dis Child 1980;55:494–5
   PubMed Web of Science ®Google Scholar
• Administration FaD. New drug application: Cafcit (NDA) 020793. Washington, DC, 2000
   Google Scholar